Differential Diagnosis of Mixed Demyelinating-Axonal Polyneuropathy
The differential diagnosis for mixed polyneuropathy should be systematically approached by first distinguishing between acquired and hereditary causes, with acquired etiologies including CIDP variants, POEMS syndrome, anti-MAG neuropathy, and cryoglobulinemia-associated neuropathy, while hereditary causes primarily involve CMTX (Cx32/GJB1 mutations), which uniquely presents with either demyelinating or axonal features. 1, 2
Acquired Causes (Immune-Mediated and Treatable)
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Atypical CIDP variants can present with mixed features when secondary axonal loss develops from chronic demyelination 3, 4
- CSF protein elevation typically present (though not required) 1
- Responds to IVIg, corticosteroids, or plasmapheresis 2
- Critical pitfall: Proximally located demyelination or predominant sensory involvement may mask demyelinating parameters on standard nerve conduction studies, leading to misclassification as axonal 3
POEMS Syndrome
- Associated with IgG or IgA λ-type monoclonal gammopathy and osteosclerotic myeloma 2
- Mixed demyelinating-axonal features common
- First-line treatment: irradiation or chemotherapy 2
Anti-MAG Neuropathy
Cryoglobulinemia-Associated Neuropathy (HCV-related)
- Mixed cryoglobulinemia (typically type II) with hepatitis C 5
- Nerve biopsy shows segmental demyelination with severe large fiber loss and onion bulb formation 5
- Responds to antiviral treatment or corticosteroids 5
Hereditary Causes
CMTX (Cx32/GJB1 Mutations)
- Uniquely presents with either predominantly demyelinating OR axonal phenotype 1
- Accounts for approximately 12% of all CMT cases 1
- Key diagnostic feature: X-linked inheritance pattern (no father-to-son transmission) 1
- Should be tested when pedigree is uninformative regarding inheritance pattern 1
CMT1 with Secondary Axonal Loss
- PMP22 duplication (CMT1A) most common, accounting for 70% of demyelinating CMT 1
- Chronic demyelination leads to secondary axonal degeneration over time 4
- PMP22 point mutations (2.5%) and MPZ mutations (5%) less common 1
Systematic Diagnostic Approach
Initial Laboratory Screening (Highest Yield Tests)
Order these three tests first 1:
- Blood glucose (highest yield - diabetes most common cause)
- Serum B12 with metabolites (methylmalonic acid ± homocysteine) - detects 44% of B12 deficiency missed by B12 alone 1
- Serum protein immunofixation electrophoresis - 10% of polyneuropathy patients have monoclonal gammopathy 1
Additional Testing Based on Clinical Context
- Glucose tolerance test: Consider if blood glucose normal but painful sensory symptoms present (25-36% have impaired glucose tolerance) 1
- Genetic testing: For patients with classical hereditary phenotype (even without family history, as 30% are de novo mutations) 1
- CSF analysis: Low yield except in demyelinating polyneuropathies (elevated protein) 1
Electrodiagnostic Strategy
Mixed features on nerve conduction studies require careful interpretation 3:
- Proximal demyelination may not be apparent on standard studies
- Secondary axonal loss in chronic demyelinating disease creates mixed picture
- Consider MRI of nerve roots/plexus if clinical suspicion for CIDP remains high despite "axonal" findings 3
Critical Diagnostic Pitfalls
- Misclassifying demyelinating neuropathy as axonal when secondary axonal loss predominates 3, 4
- Missing B12 deficiency by checking serum B12 alone without metabolites (44% false negatives) 1
- Overlooking hereditary causes in sporadic cases (76-90% of sporadic CMT1 is CMT1A; 30% of mutations are de novo) 1
- Using SPEP instead of immunofixation (misses 17% of monoclonal gammopathies, including 30% of small IgM gammopathies) 1
When to Consider Nerve Biopsy
Nerve biopsy is generally accepted as useful for 6:
- Suspected amyloid neuropathy
- Mononeuropathy multiplex due to vasculitis
- Atypical CIDP forms
However, insufficient evidence exists for routine nerve biopsy in mixed polyneuropathy 6